Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sees Large Volume Increase

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Rating) shares saw unusually-strong trading volume on Thursday . Approximately 13,227 shares traded hands during trading, a decline of 95% from the previous session’s volume of 253,934 shares.The stock last traded at $11.54 and had previously closed at $10.68.

Kiniksa Pharmaceuticals Stock Up 14.7 %

The firm has a market cap of $929.04 million, a price-to-earnings ratio of -8.28 and a beta of -0.12. The business has a 50 day moving average of $9.96 and a 200 day moving average of $10.03.

Kiniksa Pharmaceuticals (NASDAQ:KNSAGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.16. Kiniksa Pharmaceuticals had a negative return on equity of 59.47% and a negative net margin of 124.52%. The business had revenue of $32.19 million for the quarter, compared to analyst estimates of $31.93 million. During the same quarter last year, the company earned ($0.72) earnings per share. Research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -1.51 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in KNSA. Great Point Partners LLC boosted its stake in Kiniksa Pharmaceuticals by 108.3% in the 1st quarter. Great Point Partners LLC now owns 1,118,067 shares of the company’s stock worth $11,114,000 after buying an additional 581,329 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Kiniksa Pharmaceuticals by 61.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company’s stock worth $9,310,000 after buying an additional 357,387 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth about $3,570,000. Pictet Asset Management SA boosted its stake in Kiniksa Pharmaceuticals by 6.4% in the 4th quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company’s stock worth $41,768,000 after buying an additional 213,744 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Kiniksa Pharmaceuticals by 126.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company’s stock worth $3,588,000 after buying an additional 201,622 shares during the last quarter. 42.57% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

(Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Featured Articles

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.